Staff editor

The role of the microbiome in chronic lung disease

Aran Singanayagam, research group leader at Imperial College London (UK), examined how disturbances in the airway microbiome are instrumental in the development of chronic lung diseases.

EnteroBiotix embarks on groundbreaking phase 2 trial for innovative IBS treatment

Launching a new frontier in IBS management: the 'TrIuMPH' trial sets the stage with EBX-102-02, a pioneer in microbiome-based therapy.

Challenges in clinical trial execution for Live Biotherapeutics

An exclusive interview with Daniel Brownell, Senior Director of Research & Development at AOBiome Therapeutics, whose core technology is ammonia oxidizing bacteria, formulated as a topical suspension of bacteria applied…

AI implementation for microbiome small molecule discovery & therapeutics

Antonio Gomes, Principal Scientist at Xbiome, talks about employing deep learning techniques to refine the prediction of natural product structures directly from gene sets.

Innovative partnership between Resilient Biotics and Cosmosid sets a new horizon in microbiome research

The two companies will work on identifying, analyzing, and understanding respiratory tract microbiome systems.

Why microbiome therapies are the next frontier in oncology

Elran Haber, CEO at Biomica Ltd, discussed the emerging role of microbiome-based treatments in cancer care.

Expanding Horizons in Microbiome Therapeutics: List Biotherapeutics and Sacco System Forge Strategic Alliance

This partnership emerges as a strategic move to capitalize on the expanding global microbiome market.

Probiotics for women’s health: new evidence in post-menopausal women

Harnessing the benefits of L. plantarum PBS067, L. rhamnosus LRH020, and B. lactis BL050 for post-menopausal symptom relief.

Freya Biosciences: pioneering the development of microbial immunotherapies for women’s health

Johan van Hylckama Vlieg, CSO and Co-founder of Freya Biosciences, discusses the latest advancements in microbial immunotherapies for women's health.

The PICASSO trial: painting a new future for melanoma patients

MaaT Pharma indicates completion of patient recruitment for the Phase 2a RCT Evaluating MaaT013 in combination with immune checkpoint inhibitors in metastatic melanoma.

Subscribe to MicrobiomePost newsletter

Take full advantage of MicrobiomePost‘s features.

Scroll to Top